Loading
A phase 2 trial of nab-paclitaxel, carboplatin and cyclophosphamide in triple-negative breast cancer, run by Shandong Cancer Hospital and Institute, now recruiting.
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer is a phase 2, randomised interventional study registered as NCT06802757 by Shandong Cancer Hospital and Institute, with a registry enrolment figure of 72 participants, started 2025-05-01 and due to reach its primary completion in 2026-06-30. Interventions recorded: Posaconazole; Nab-paclitaxel; Carboplatin; Anthracycline; Cyclophosphamide; PD-1 inhibitors. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "first-confirmed TNBC;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.